Original Article
The 1012C>G polymorphism of nucleobindin 2 is associated with the development of coronary artery disease

Yingli Lin1, Ruiying Su2, Jianguo Ma3

1Department of Urology, Affiliated Xuzhou Hospital of Jiangsu University, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, China; 2First Department of Cardiovascular, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; 3Department of Urology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Received September 8, 2015; Accepted December 5, 2015; Epub February 15, 2016; Published February 29, 2016

Abstract: Objective: Nucleobindin 2 (NUCB2) is a precursor of nesfatin-1 which is a hypothalamic anorectic neuropeptide. Nesfatin-1 is found to be involved in the pathogenesis of coronary artery disease (CAD). Our study is designed to examine whether the 1012C>G polymorphism of NUCB2 gene is associated with an increased risk of developing CAD in Chinese Han population. Methods: This study consisted of 285 patients with CAD and 117 healthy subjects. Polymerase chain reaction and direct sequencing method was utilized to examine 1012C>G polymorphism of NUCB2 gene in this population. Results: CG and GG genotype frequencies of NUCB2 polymorphism was significantly reduced in CAD patients than those in healthy controls. Furthermore, there is lower G allele frequency in CAD patients compared with healthy controls. Conclusions: 1012C>G polymorphism of NUCB2 gene is associated with the development of CAD in Chinese Han population.

Keywords: Polymorphism, nucleobindin 2, nesfatin-1, coronary artery disease

Introduction
Coronary artery disease (CAD) is a major cause of mortality worldwide. Insulin resistance, dyslipidemia, hypertension, family history, obesity, and smoking are considered to be traditional risk factors for CAD development [1]. In addition, genetic factors also contribute to the incidence of CAD [2]. A variety of studies have focused on the genetic susceptibility to CAD and found that more and more gene polymorphisms are associated with an increased risk of developing CAD [3].

Nucleobindin 2 (NUCB2), is a precursor of nesfatin-1 which is a neuropeptide widely expressed in the central nervous system. Nesfatin-1 regulates appetite and energy metabolism. Intracerebroventricular injection of nesfatin-1 caused decreased nocturnal food intake and body weight gain [4]. Nesfatin-1 plays an important role in the mechanism of cardiovascular diseases including CAD. Nesfatin-1 depressed the contractility and relaxation of cardiomyocytes and limited ischemia/reperfusion damage, acting in post-conditioning protection [5]. Dai et al. reported that plasma nesfatin-1 levels were significantly lower in acute myocardial infarction group control group [6]. Recently, a genetic polymorphism (1012C>G) in NUCB2 gene was found in obese populations [7, 8]. It is plausible that this genetic variant in NUCB2 gene may influence an individual’s susceptibility to CAD.

The aim of this study is to examine the association of the 1012C>G polymorphism of NUCB2 gene with the risk of CAD in Chinese Han population.

Materials and methods
Subjects
A consecutive population of 285 patients with angiographically proven CAD was enrolled in our study. CAD was defined as subjects who had angiographic evidence of stenosis ≥50% in
Nucleobindin 2 polymorphism with CAD

Table 1. Anthropometric and metabolic characteristics parameters of the patients with CAD and control subjects

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>CAD (n=285)</th>
<th>Control (n=117)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60.65±9.84</td>
<td>59.21±10.62</td>
<td>0.195</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>136/106</td>
<td>49/37</td>
<td>0.901</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.69±2.97</td>
<td>24.41±2.35</td>
<td>0.370</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>142.66±14.42</td>
<td>124.02±13.98</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>84.23±10.29</td>
<td>82.06±8.96</td>
<td>0.047</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.67±0.91</td>
<td>1.08±0.47</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TC (mmol/L)</td>
<td>5.12±1.09</td>
<td>4.97±0.93</td>
<td>0.203</td>
</tr>
<tr>
<td>HDL-C (mmol/L)</td>
<td>1.10±0.22</td>
<td>1.52±0.22</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL-C (mmol/L)</td>
<td>3.45±0.73</td>
<td>2.99±0.44</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are given as mean ± SD. Abbreviations: CAD, coronary artery disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

at least one major coronary artery. The control group consisted of 117 age- and sex-matched subjects who were recruited from individuals attending the routine check up in our hospital. All control subjects were free of personal or family history of cardiovascular or hemorrhagic disease. The study protocol was approved by the Human Ethics Review Committee of our hospital and a signed consent form was obtained from each subject.

Measurements

Weight, height, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Venous blood was obtained in the fasting state at 7:00 am after overnight. Serum triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were measured by auto biochemistry instrument (Hitachi 7170, Tokyo, Japan). Body mass index (BMI) was calculated as weight in kilograms divided by height squared in meters (kg m⁻²).

DNA genotyping

Blood samples were collected from 285 patients with CAD and 117 healthy subjects. Genomic DNA from all the subjects was extracted from peripheral blood leukocytes using a DNA isolation kit following the manufacturer’s instructions (Qiagen). Genotyping of G1359A polymorphism of CNR1 was performed using polymerase chain reaction and then direct sequencing.

Statistical analysis

Statistical analysis was performed using SPSS version 16.0 software. Data are presented as mean ± standard deviation (SD). Biochemical variables were compared between case and control group using the Student t-test. A chi square test was performed to examine Hardy-Weinberg equilibrium. The genotype and allele frequencies were compared using the χ² test. Two-tailed P<0.05 was considered statistically significant.

Results

The baseline parameters

As shown in Table 1, CAD group showed higher levels of SBP, DBP, TG, LDL-C, and lowered HDL-C level than the control subjects. No significant differences were observed in other characteristics between the two groups.

Association of the polymorphism with the development of CAD

The genotype frequencies of 1012C>G polymorphism among the controls were in agreement with Hardy-Weinberg equilibrium (P=0.853). As presented in Table 2, CG and GG genotype frequencies of NUCB2 polymorphism was significantly reduced in CAD patients than those in healthy controls. Furthermore, there is lower G allele frequency in CAD patients compared with healthy controls.

Discussion

Nesfatin-1 is an 82-amino acid protein encoded by the nucleobindin 2 gene. Nesfatin-1 is expressed in several hypothalamic nuclei and extra-hypothalamic areas [9]. Nesfatin-1 plays an important role in the cardiovascular function by regulating blood pressure. Intracerebroventricular administration of nesfatin-1 could interact with the central melanocortin system to increase sympathetic nerve activity and lead to an increase in mean arterial pressure in conscious rats [9]. Mimee et al. reported that microinjection of nesfatin-1 into the medial
Table 2. Distribution of CNR1 gene polymorphism among the subjects with CAD and control subjects

<table>
<thead>
<tr>
<th>Genotype</th>
<th>CAD group (n=285)</th>
<th>Control group (n=117)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>CC</td>
<td>131</td>
<td>46.0</td>
<td>42</td>
</tr>
<tr>
<td>CG</td>
<td>136</td>
<td>47.7</td>
<td>57</td>
</tr>
<tr>
<td>GG</td>
<td>18</td>
<td>6.3</td>
<td>18</td>
</tr>
<tr>
<td>C</td>
<td>398</td>
<td>69.8</td>
<td>141</td>
</tr>
<tr>
<td>G</td>
<td>172</td>
<td>30.2</td>
<td>93</td>
</tr>
</tbody>
</table>

The nucleus of the solitary tract induced significant increases in blood pressure [10]. Chronic peripheral nesfatin-1 administration also increased blood pressure in rats [11]. Recently, 1012C>G polymorphism of NUCB2 gene is demonstrated to be correlated with blood pressure [12].

Nesfatin-1 also regulates cardiac function. Nesfatin-1 protein and NUCB2 mRNA were expressed in rat cardiac extracts. Exogenous nesfatin-1 depressed heart contractility and relaxation without affecting coronary motility [13]. Microinjection of nesfatin-1 into nucleus ambiguus activated cardiac vagal neurons of nucleus ambiguus and elicited bradycardia in conscious rats [14]. Nesfatin-1 protected against cardiac ischemia/reperfusion injury by reducing infarct size, lactate dehydrogenase release, and post-ischemic contracture [13]. Plasma nesfatin-1 levels were significantly lower in acute myocardial infarction group control group [6]. These results indicate the important role of nesfatin-1 in cardiac function and possible protective effects in the development of CAD. Our investigation found a significant association of NUCB2 polymorphism with the occurrence of CAD. Therefore, NUCB2 polymorphism may serve as a genetic risk factor for CAD. Subjects with CC genotype are considered to be risk population for CAD and should perform some preventive strategies such as changing life style, weight loss, or statin treatment.

Obesity is a clear risk factor for CAD. Obesity also increases the risk for developing traditional CAD risk factors including hypertension, dyslipidemia, and diabetes mellitus, resulting in a greater occurrence of CAD. Numerous investigations have demonstrated the association of obesity with angina, myocardial infarction (MI), heart failure, and sudden cardiac death [15]. Nesfatin-1 is a peptide closely correlated with appetite and obesity [16]. Intracerebroventricular injection of nesfatin-1 caused decreased nocturnal food intake and body weight gain [4]. Recent studies have found reduced plasma nesfatin-1 concentrations in obese patients [4]. In addition, an association of 1012C>G polymorphism of NUCB2 gene with obesity was observed recently [7, 8]. Therefore, this polymorphism may contribute to the development of CAD through obesity-related mechanism.

It should be mentioned, however, that the current study inevitably has some limitations. First, this study had a relatively small population size. Second, as our study was only conducted in a sample of Chinese Han population, the result is lack of replication in other population. Therefore, our data should be validated in prospective studies with a larger population size in other ethnic populations.

Our data provides evidence for the first time that the 1012C>G polymorphism of NUCB2 gene is associated with an increased risk of CAD in the Chinese Han population. Further studies are necessary to determine the exact mechanism by which this polymorphism could influence the risk of developing CAD.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Ruiying Su, First Department of Cardiovascular, Third Hospital of Hebei Medical University, No 139 Ziqiang Road, Shijiazhuang, 050051, Hebei Province, China. Tel: 86-311-88602026; Fax: 86-311-88602026; E-mail: surysjz@126.com

References


Nucleobindin 2 polymorphism with CAD


